Medical Condition

myelofibrosis

Total Trials

8

Recruiting Now

8

Trial Phases

Phase 2, Phase 1, Phase 1, Phase 2

ClinicalMetric tracks all active clinical trials for myelofibrosis sourced from ClinicalTrials.gov. Research in this area spans early-phase safety investigations through large Phase 3 confirmatory trials, conducted by NIH-funded academic centers, independent investigators, and pharmaceutical sponsors worldwide. Each listing is updated daily as new studies open enrollment and existing ones reach capacity or complete follow-up.

Trial listings include the NCT identifier, current recruitment status, phase classification, primary and secondary endpoints, estimated enrollment size, participating countries, and direct links to the full protocol on ClinicalTrials.gov. Eligibility criteria — including age range, disease stage, and prior treatment requirements — are documented for every study to help patients and clinicians assess suitability before contacting a trial site.

Frequently Asked Questions — myelofibrosis Clinical Trials

How many clinical trials are currently recruiting for myelofibrosis?

ClinicalMetric currently tracks 8 actively recruiting clinical trials for myelofibrosis, sourced in real time from ClinicalTrials.gov. The total number of registered studies—including those not yet enrolling or in active follow-up—is 8. Trial availability changes daily as new studies open enrollment and existing ones reach capacity.

What trial phases are available for myelofibrosis?

myelofibrosis research spans Phase 1 (4 trials), Phase 2 (5 trials). Phase 1 studies evaluate safety and dosing in small groups, Phase 2 studies assess preliminary efficacy in 100–300 participants, and Phase 3 trials compare the new treatment against the standard of care in 300–3,000+ patients. Phase 4 post-approval studies monitor long-term outcomes in real-world populations.

How do I find out if I qualify for a myelofibrosis clinical trial?

Eligibility criteria for myelofibrosis trials vary by study and typically specify age range, disease stage or severity, prior treatment history, and specific diagnostic or laboratory parameters. Each listing on ClinicalMetric links to the full protocol on ClinicalTrials.gov, where inclusion and exclusion criteria are documented. Contact the sponsoring site's research coordinator directly to confirm your eligibility—your treating physician or specialist can also help identify the most appropriate trial based on your medical history and current treatment status.

Trial Phases

Phase 1

Phase 2

Top Sponsors

University of California, Irvine 2 trials

Ryvu Therapeutics SA 1 trial

Cellenkos, Inc. 1 trial

Masonic Cancer Center, University of Minnesota 1 trial

Center for International Blood and Marrow Transplant Research 1 trial

Recruiting Clinical Trials

NCT06397313 Phase 2

Recruiting

RVU120 in Patients With Intermediate or High-risk, Primary or Secondary Myelofibrosis

Leading in MPNs Beyond Ruxolitinib in Combo With T-Regs

NCT07281781 Phase 1, Phase 2

Recruiting

Treating Anemia in Myelofibrosis With Repurposed Drugs (Nelfinavir) That Restore Iron Delivery to the Bone Marrow

University of California, Irvi...

View Trial →

NCT05805605 Phase 2

Recruiting

Allo HSCT Using RIC and PTCy for Hematological Diseases

Masonic Cancer Center, Univers...

View Trial →

NCT05123365 Phase 1, Phase 2

Recruiting

An Optimal Dose Finding Study of N-Acetylcysteine in Patients With Myeloproliferative Neoplasms

University of California, Irvi...

View Trial →

NCT02934477

Recruiting

Prospective Assessment of Allogeneic Hematopoietic Cell Transplantation in Patients With Myelofibrosis

Center for International Blood...

View Trial →

NCT03964506 EARLY_Phase 1

Recruiting

Hyperbaric Oxygen Therapy and Allogeneic Peripheral Blood Stem Cell (PBSC) Transplant

High Dose Ruxolitinib and Allogeneic Stem Cell Transplantation in Myelofibrosis Patients With Splenomegaly

M.D. Anderson Cancer Center

View Trial →

Related Conditions

myelodysplastic syndromes (2) myeloproliferative neoplasm (2) myelofibrosis anemia (1) acute myelogenous leukemia (1) acute lymphocytic leukemia (1) biphenotypic acute leukemia (1) undifferentiated leukemia (1) prolymphocytic leukemia (1) chronic myelogenous leukemia (1) plasma cell leukemia (1) leukemia myeloid (1) myelodysplastic syndrome with excess blasts 1 (1)

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer · Last Reviewed: April 2026 · Data Methodology